ArticleIndian journal of pediatrics2026
Predictors of Failure of Conventional Dose Caffeine Therapy in Neonates Below 32 Weeks' Gestation: An Ambispective Cohort Study.
Article in Indian journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesOver half of all preterm neonates started on conventional maintenance-dose caffeine therapy require dose escalation. This study aimed to determine the predictors of failure of conventional maintenance-dose caffeine therapy for apnea of prematurity, which may guide individualized dosing regimens.
methodsIn this ambispective cohort study, the authors enrolled neonates <32 wk gestation receiving caffeine therapy, retrospectively (Jan 2019-Dec 2020) and prospectively (Aug 2021-Dec 2022). Conventional dose was defined as caffeine citrate, 20 mg/kg loading followed by 5 mg/kg/d. 'Failure' was defined as clinician-driven escalation of maintenance-dose. Predictor variables differing between the failure and success groups were analyzed using multivariable logistic regression. Additional outcomes included prediction of plasma caffeine levels using regression analysis of clinical variables.
resultsA total of 164 neonates (70 prospective, 94 retrospective) were enrolled (gestation 28.7 ± 1.8 wk). Failure occurred in 94 (57%; 95% CI 49-65) neonates. Only gestation independently predicted caffeine failure on multivariable analysis; each one-week increase in gestation nearly halved the odds of treatment failure (aOR: 0.55; 95% CI 0.41-0.72). Neonates with gestation <28 wk had significantly higher odds of having caffeine failure compared to those ≥28 wk gestation (92% vs. 46%; OR 14.5, 95% CI 4.2-49.5). Regression model showed a significant positive association between caffeine dose and plasma caffeine levels (β = 0.59, p <0.001); other variables were not statistically significant.
conclusionsIn neonates below 32 wk gestation, lower gestation predicts failure of conventional-dose caffeine therapy. Higher initial maintenance doses warrant further exploration in neonates below 28 wk.
Indexed as
Identifiers
42825891What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.